NasdaqGS - Nasdaq Real Time Price USD
Zenas BioPharma, Inc. (ZBIO)
9.25
-0.04
(-0.43%)
As of 1:55:36 PM EDT. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
Total Revenue
5,000
5,000
50,000
0
Operating Expense
168,888
168,888
77,147
75,199
Operating Income
-163,888
-163,888
-27,147
-75,199
Other Income Expense
7,329
7,329
-9,676
-44,083
Pretax Income
-156,559
-156,559
-36,823
-119,282
Tax Provision
429
429
301
0
Net Income Common Stockholders
-156,988
-156,988
-37,124
-119,282
Diluted NI Available to Com Stockholders
-156,988
-156,988
-37,124
-119,282
Basic EPS
-11.89
--
-2.13
-9.26
Diluted EPS
-11.89
--
-2.13
-9.26
Basic Average Shares
13,198.96
--
17,415.88
12,879.65
Diluted Average Shares
13,198.96
--
17,415.88
12,879.65
Total Operating Income as Reported
-163,888
-163,888
-37,147
-76,199
Total Expenses
168,888
168,888
77,147
75,199
Net Income from Continuing & Discontinued Operation
-156,988
-156,988
-37,124
-119,282
Normalized Income
-156,988
-156,988
-29,224
-105,014
EBIT
-163,888
-163,888
-27,147
-75,199
EBITDA
-163,751
-163,751
-27,034
-75,121
Reconciled Depreciation
137
137
113
78
Net Income from Continuing Operation Net Minority Interest
-156,988
-156,988
-37,124
-119,282
Total Unusual Items Excluding Goodwill
0
0
-10,000
-14,268
Total Unusual Items
0
0
-10,000
-14,268
Normalized EBITDA
-163,751
-163,751
-17,034
-60,853
Tax Rate for Calcs
0
0
0
0
Tax Effect of Unusual Items
0
0
-2,100
0
12/31/2022 - 9/13/2024
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
UPB Upstream Bio, Inc.
9.11
+3.05%
KROS Keros Therapeutics, Inc.
13.75
-1.93%
DNTH Dianthus Therapeutics, Inc.
19.74
-4.27%
MBX MBX Biosciences, Inc.
11.01
-5.98%
BCAX Bicara Therapeutics Inc.
12.78
-2.67%
SYRE Spyre Therapeutics, Inc.
14.31
+11.28%
ALMS Alumis Inc.
5.14
-3.38%
KYTX Kyverna Therapeutics, Inc.
2.0700
-2.82%
APGE Apogee Therapeutics, Inc.
37.49
-0.85%
CNTA Centessa Pharmaceuticals plc
12.26
-1.05%